Considering the consistently poor prognoses for some of the deadliest cancers, as well as the skyrocketing costs (~$1-2 billion) and long time frame (~12-16 years) for developing a brand-new drug, rapidly translatable agents that offer improvements in outcomes are much needed. Drug repurposing is one such strategy to decrease costs, reduce time frame to clinical translation, and possibly increase success rates. This presentation will elucidate the benefit of this approach with drugs like the tetracyclines (a class of antibiotics), vitamins and chemotherapeutics combined with PDT to overcome chemoresistance in pancreatic and ovarian cancers.
|